US2024000928A1PendingUtilityA1

Approach for treatment of cancer via immunomodulation by using talabostat

60
Assignee: ONKOSXCEL THERAPEUTICS LLCPriority: Jul 16, 2015Filed: Dec 21, 2022Published: Jan 4, 2024
Est. expiryJul 16, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Luca RastelliAparna Katoch SapraVimal Mehta
A61K 39/3955A61K 38/04C12N 15/1137A61K 45/06A61K 39/39541A61K 31/69C07K 16/2818A61K 2039/505A61K 31/198A61P 35/00A61P 35/04C12N 2310/14C12N 2320/31A61K 2039/545C07K 2317/76A61P 35/02A61P 37/04A61P 43/00C07K 2317/21A61K 31/40A61K 39/395
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising an effective amount of Talabostat and an effective amount of Nivolumab.

Join the waitlist — get patent alerts

Track US2024000928A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.